KR920703803A - 활성화 피브린 용해성과 항-혈전성 단백질 - Google Patents
활성화 피브린 용해성과 항-혈전성 단백질Info
- Publication number
- KR920703803A KR920703803A KR1019920701348A KR920701348A KR920703803A KR 920703803 A KR920703803 A KR 920703803A KR 1019920701348 A KR1019920701348 A KR 1019920701348A KR 920701348 A KR920701348 A KR 920701348A KR 920703803 A KR920703803 A KR 920703803A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- compound according
- nucleic acid
- protein
- coagulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/70—Vector systems having a special element relevant for transcription from fungi
- C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
- C12N2830/704—S. cerevisiae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/107—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translational read-through
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
Abstract
내용 없음
Description
활성화 피브린 용해성과 항-혈전성 단백질
[도면의 간단한 설명]
제1도는 pGWH의 구조도.
제3도는 표현 벡터 pGWHgP1의 지도.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (25)
- 피브린 용해 활성을 갖기 위하여 또는 응혈 형성을 억제하기 위하여, 응혈에 포함되어 있는 효소에 의하여 활성화할 수 있는 단백질 화합물에 있어서, 이 화합물이 플라스민 활성을 갖도록 활성화할 수 있는 플라스미노겐 유사체임을 특징으로 하는 상기 화합물.
- 제1항에 있어서, 응혈에 포함되어 있는 효소가 칼리크레인, 인자 XIIa, XIa, IXa, VIIa, Xa, 트롬빈(인자 IIa) 또는 활성화 단백질 C임을 특징으로 하는 화합물.
- 제1항 또는 제2항에 있어서, 응혈에 포함되어 있는 효소가 인자 Xa 또는 트롬빈임을 특징으로 하는 화합물.
- 제1항 또는 제2항에 있어서, 응혈에 포함되어 있는 효소가 인자 Xa임을 특징으로 하는 화합물.
- 제4항에 있어서, P4가 소수성 잔재를 나타내고 P3가 산성 잔재를 나타내는 전단 부위 배열 P4-P3-Gly-Arg을 함유함을 특징으로 하는 화합물.
- 제5항에 있어서, 소수성 잔재가 이소류신임을 특징으로 하는 화합물.
- 제1항 또는 제2항에 있어서, 응혈에 포함되어 있는 효소가 트롬빈임을 특징으로 하는 화합물.
- 제7항에 있어서, P4와 P3가 각각 독립적으로 소수성 잔재를 나타내고 P1'와 P2'가 각각 독립적으로 비-산성 잔재를 나타내는 절단부위 배열 Pro-P3-Pro-Arg-P1′-P2′를 함유함을 특징으로 하는 화합물.
- 제7항에 있어서, 잔재 P2와 P1′ 중 하나가 글리신을 나타내고, 다른 하나가 아미노산 잔재를 나타냄을 특징으로 하는 화합물.
- 제7항에 있어서, 절단 부위 배열 Gly-Pro-Arg를 함유함을 특징으로 하는 화합물.
- 제1항에 있어서, 포함된 잔재 Pro(55)와 Cys(566)사이에 하나 또는 그 이상의 아미노산 치환물, 첨가물 또는 결실물을 가짐을 특징으로 하는 화합물.
- 제1항 또는 제11항에 있어서, 하나 또는 그 이상의 첨가물, 결실물 또는 치환물일 수 있는 하나 또는 그 이상 다른 변경물(야생형 qlu-플라스미노겐과 비교하여)을 함유함을 특징으로 하는 화합물.
- 연속 아미노산 잔재를 함께 결합시키고 올리고-과 또는 폴리-펩티드를 결합시킴을 특징으로 하는 제1항 내지 제12항 중 어느 한 항의 단백질 화합물의 제조방법.
- 제1항 내지 제12항 중 어느 한 항의 단백질 화합물을 암호화하는 합성 또는 재조합형 핵산.
- 제14항에 있어서, 벡터임을 특징으로 하는 핵산.
- 연속 누클레오티드를 함께 결합시키고 올리고-과/또는 폴리-누클레오티드를 결합시킴을 특징으로 하는 제14항의 핵산의 제조방법.
- 인체 시토메갈로바이러스에서 유도된 강한 프로모터와 인헨서 배열을 함유하는 제2핵산 배열에 조작적으로 연결되는 단백질을 암호화하거나 클론 부위를 규현하는 제1핵산 배열, SV40에서 유도된 폴리아데닐화 배열을 기호화하는 제3핵산 배열과 SV40 프로모터로부터 표현된 qpt선택성 표지를 암호화하고 선택성 표지 배열의 3'말단에서 부가적 SV40 폴리아데닐화 신호를 갖는 제4핵산 배열로 이루어짐을 특징으로 하는 벡터.
- 제17항에 있어서, 제1핵산 배열이 플라스미노겐 또는 플라스미노겐 유사체를 암호화함을 특징으로 하는 벡터.
- 제15항, 제17항 또는 제18항에서 특허청구된 벡터로 형질전환되거나, 트란스펙트된 세포 또는 세포선.
- 제19항에 있어서, 연속 배양으로 성장하는 포유류 세포로 이루어지는 세포선.
- 플라스미노겐 또는 플라스미노겐 유사체를 표현하도록 형질 전환된 중국 햄스터 난소 세포.
- 제1항 내지 제12항 중 어느 한 항의 하나 또는 그 이상 화합물과 약학적 또는 수의학적으로 허용할 수 있는 담체로 이루어짐을 특징으로 하는 제약적 조성물.
- 비독성, 유효량의 제1항 내지 제12항중 어느 한 항의 화합물을 투여하여서 함을 특징으로 하는 혈전성 질별의 치료 또는 예방방법.
- 의약품 또는 수의약품으로 사용하는 제1항 내지 제12항중 어느 한 항의 단백질 화합물.
- 혈전 분해제 또는 항혈전제를 제조하는데 제1항 내지 제12항중 어느 한 항의 화합물을 상요하는 화합물의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB89277222 | 1989-12-07 | ||
GB8927722.2 | 1989-12-07 | ||
GB898927722A GB8927722D0 (en) | 1989-12-07 | 1989-12-07 | Proteins and nucleic acids |
PCT/GB1990/001912 WO1991009118A2 (en) | 1989-12-07 | 1990-12-07 | Activatable fibrinolytic and anti-thrombotic proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
KR920703803A true KR920703803A (ko) | 1992-12-18 |
KR100188302B1 KR100188302B1 (ko) | 1999-06-01 |
Family
ID=10667597
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920701348A KR100188302B1 (ko) | 1989-12-07 | 1990-12-07 | 활성화피브린용해성과항-혈전성단백질 |
KR1019920701305A KR920703818A (ko) | 1989-12-07 | 1990-12-07 | 단백질과 핵산 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920701305A KR920703818A (ko) | 1989-12-07 | 1990-12-07 | 단백질과 핵산 |
Country Status (21)
Country | Link |
---|---|
US (2) | US5434073A (ko) |
EP (2) | EP0502968B1 (ko) |
JP (2) | JPH05502374A (ko) |
KR (2) | KR100188302B1 (ko) |
AT (1) | ATE155812T1 (ko) |
AU (3) | AU644399B2 (ko) |
CA (2) | CA2069105A1 (ko) |
DE (1) | DE69031127T2 (ko) |
DK (1) | DK0502968T3 (ko) |
ES (1) | ES2106073T3 (ko) |
FI (2) | FI922609A (ko) |
GB (1) | GB8927722D0 (ko) |
GR (1) | GR3024990T3 (ko) |
HU (1) | HU211628A9 (ko) |
IE (2) | IE81046B1 (ko) |
IL (2) | IL96601A (ko) |
NO (2) | NO305562B1 (ko) |
NZ (2) | NZ236330A (ko) |
PT (2) | PT96103B (ko) |
WO (2) | WO1991009118A2 (ko) |
ZA (2) | ZA909853B (ko) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22277A1 (es) * | 1990-05-23 | 1995-01-31 | Cigb | Procedimiento para el aislamiento y expresion de un gen codificante para estreptoquinasa,secuencia nucleotidica obtenida,adn recombinantes y microorganismos transformados |
GB9222758D0 (en) * | 1992-10-29 | 1992-12-09 | British Bio Technology | Proteins and nucleic acids |
GB9216558D0 (en) * | 1992-08-04 | 1992-09-16 | British Bio Technology | Modified proteases |
GB2286190B (en) * | 1992-10-29 | 1996-05-01 | British Biotech Pharm | Thrombin activatable plasminogen derivatives |
DE4323754C1 (de) * | 1993-07-15 | 1994-12-01 | Gruenenthal Gmbh | Bifunktionelle Urokinasevarianten mit verbesserten fibrinolytischen Eigenschaften und thrombinhemmender Wirkung |
US5661001A (en) * | 1993-08-04 | 1997-08-26 | Ciba-Geigy Corporation | High molecular weight desulphatohirudin |
ES2080657B1 (es) * | 1993-09-27 | 1996-11-01 | Britisch Bio Technology Limite | Proteasas modificadas. |
CN1309833C (zh) * | 1994-04-26 | 2007-04-11 | 儿童医学中心公司 | 血管生成抑制素及其在制备药物中的用途 |
US5945403A (en) | 1997-05-30 | 1999-08-31 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
GB9412131D0 (en) * | 1994-06-17 | 1994-08-10 | British Bio Technology | Thrombolytic composition |
DE4440892A1 (de) * | 1994-11-17 | 1996-05-23 | Gruenenthal Gmbh | Proteine mit fibrinolytischen und gerinnungshemmenden Eigenschaften |
DE4442665A1 (de) * | 1994-11-30 | 1996-06-05 | Gruenenthal Gmbh | Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften |
US5854049A (en) * | 1995-06-09 | 1998-12-29 | President And Fellows Of Harvard College | Plasmin-resistant streptokinase |
US5736364A (en) * | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
US6461640B1 (en) | 1995-12-08 | 2002-10-08 | Board Of Regents, The University Of Texas System | Local delivery of fibrinolysis enhancing agents |
TR199900193T2 (xx) * | 1996-08-02 | 1999-03-22 | Boehringer Mannheim Gmbh | Trombin ile aktifleştirilebilen plazminojen aktifleştiricisi. |
CA2290485C (en) * | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
PT947585E (pt) | 1998-03-19 | 2001-11-30 | Instrumentation Lab Spa | Metodo in vitro melhorado, kits e reagentes para a peaquisa de defeitos de coagulacao sanguinea |
WO2000010506A2 (en) | 1998-08-20 | 2000-03-02 | University Of Vermont And State Agriculture College | Angiogenesis inhibitors and uses thereof |
IN190822B (ko) * | 1998-12-24 | 2003-08-23 | Council Scient Ind Res | |
WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
US7160540B2 (en) | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
CA2421251A1 (en) * | 2000-09-05 | 2002-03-14 | Karolinska Innovations Ab | Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
DE10108211A1 (de) * | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen |
DE10108100A1 (de) * | 2001-02-20 | 2002-08-29 | Aventis Pharma Gmbh | Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse |
US7638618B2 (en) | 2001-02-20 | 2009-12-29 | Sanofi-Aventis Deutschland Gmbh | Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest |
US7202059B2 (en) | 2001-02-20 | 2007-04-10 | Sanofi-Aventis Deutschland Gmbh | Fusion proteins capable of being secreted into a fermentation medium |
DE10108212A1 (de) * | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände |
FR2831170B1 (fr) * | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
CA2475388A1 (en) * | 2002-02-14 | 2003-08-21 | William J. Rutter | Chimeric molecules for cleavage in a treated host |
CN1480466A (zh) * | 2002-09-03 | 2004-03-10 | �й������ž�����ҽѧ��ѧԺ����ҽ | 一类溶栓抗凝双功能融合蛋白及应用 |
US7985401B2 (en) | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
US9695251B2 (en) | 2003-10-31 | 2017-07-04 | The Regents Of The University Of California | Activatable cell penetrating peptides with quenched fluorophores |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
WO2007144173A1 (en) | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
CN101730740A (zh) * | 2006-09-29 | 2010-06-09 | 蛋白质组技术公司 | 用于生产重组纤溶酶原和纤溶酶多肽的方法 |
CN1970574B (zh) * | 2006-12-08 | 2010-08-25 | 中国药科大学 | 溶栓和抗凝双重功效融合蛋白、制备方法及其应用 |
JP5448839B2 (ja) | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | インビボで長い半減期を有する修飾された凝固因子 |
US8501449B2 (en) | 2007-12-04 | 2013-08-06 | Proteon Therapeutics, Inc. | Recombinant elastase proteins and methods of manufacturing and use thereof |
WO2010045518A1 (en) * | 2008-10-16 | 2010-04-22 | The Trustees Of The University Of Pennsylvania | Compositions containing thrombomodulin domains and uses thereof |
EP3243835B1 (en) | 2009-02-11 | 2024-04-10 | Albumedix Ltd | Albumin variants and conjugates |
WO2011008996A2 (en) * | 2009-07-15 | 2011-01-20 | The Regents Of The University Of California | Peptides whose uptake in cells is controllable |
GB2488077A (en) | 2009-10-30 | 2012-08-15 | Novozymes Biopharma Dk As | Albumin variants |
CL2011001887A1 (es) * | 2010-08-05 | 2012-02-03 | Council Scient Ind Res | Construcciones de proteinas quimericas que poseen propiedades anticoagulantes y tromboliticas; secuencia de acido nucleico que las codifica; vector; celula huesped; metodo de preparacion; formulacion farmaceutica que las comprende; y su uso para inhibir la trombina. |
AU2012290318B2 (en) | 2011-07-29 | 2016-09-01 | Avelas Biosciences, Inc. | Selective delivery molecules and methods of use |
WO2013024074A1 (en) * | 2011-08-12 | 2013-02-21 | Thrombogenics N.V. | Plasminogen and plasmin variants |
US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
MX2014010278A (es) | 2012-03-16 | 2015-03-05 | Novozymes Biopharma Dk As | Variantes de albumina. |
CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
WO2014120837A2 (en) | 2013-01-29 | 2014-08-07 | The Regents Of The University Of California | Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug |
WO2014120974A1 (en) | 2013-01-30 | 2014-08-07 | Avelas Biosciences, Inc. | Selective delivery molecules and methods of use |
EP3318124A3 (en) | 2013-02-16 | 2018-05-30 | Albumedix A/S | Pharmacokinetic animal model |
US10385380B2 (en) | 2014-10-02 | 2019-08-20 | The Regents Of The University Of California | Personalized protease assay to measure protease activity in neoplasms |
US10596259B2 (en) | 2015-05-20 | 2020-03-24 | The Regents Of The University Of California | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof |
AU2016308504A1 (en) | 2015-08-20 | 2018-01-18 | Albumedix Ltd. | Albumin variants and conjugates |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1897087A (en) * | 1927-12-14 | 1933-02-14 | Tamarin Bernard Jacques | Vacuum cleaner cord control device |
US3608333A (en) * | 1968-06-20 | 1971-09-28 | Bison Mfg Co Inc | Vacuum cleaner and power unit |
US4880776A (en) * | 1983-12-24 | 1989-11-14 | Beecham Group P.L.C. | Plasmin A-chain urokinase B-chain hybrid protein |
GB8334498D0 (en) * | 1983-12-24 | 1984-02-01 | Beecham Group Plc | Compounds |
DE3410437A1 (de) * | 1984-03-22 | 1985-09-26 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von proteinen |
GB8412517D0 (en) * | 1984-05-16 | 1984-06-20 | Nagai K | Recombinant fusion proteins |
US5087564A (en) * | 1985-06-20 | 1992-02-11 | Monsanto Company | Release of recombinant peptides from polypeptides using V8 endopeptidase |
DE3523701A1 (de) * | 1985-07-03 | 1987-01-08 | Bayer Ag | Verfahren zur herstellung von proteinen und polypeptiden |
DE3526995A1 (de) * | 1985-07-27 | 1987-02-05 | Hoechst Ag | Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung |
DE3541856A1 (de) * | 1985-11-27 | 1987-06-04 | Hoechst Ag | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens |
DK275788A (da) * | 1987-05-22 | 1989-02-03 | Zymogenetics Inc | Fibrinolytiske proteiner |
US5200340A (en) * | 1987-05-22 | 1993-04-06 | Zymogenetics, Inc. | Thrombin-activated tissue plasminogen activators |
EP0296413A2 (en) * | 1987-06-12 | 1988-12-28 | Hoechst Japan Limited | Hybrid protein C and method for its preparation |
HUT47151A (en) * | 1987-07-01 | 1989-01-30 | Beecham Group Plc | Process for producing new hybrid plasminogen activator compounds |
GB8717430D0 (en) * | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
CA1340802C (en) * | 1987-08-15 | 1999-10-26 | Yasuyuki Takahashi | Senile amyloid precursor protein and an antibody specific for the same |
DE3886517T2 (de) * | 1987-08-19 | 1994-04-21 | Sagami Chem Res | Menschlicher Prourokinase ähnliches Polypeptid. |
CA1340740C (en) * | 1987-12-08 | 1999-09-14 | Eileen R. Mulvihill | Co-expression in eukaryotic cells |
ZA889497B (en) * | 1987-12-28 | 1990-08-29 | Lilly Co Eli | Vectors and compounds for expression of zymogen forms of human protein c |
CA1340877C (en) * | 1987-12-28 | 2000-01-18 | Takashi Sugiyama | Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology |
DE3804600A1 (de) * | 1988-02-13 | 1989-08-24 | Basf Ag | Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz |
GB8809129D0 (en) * | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
GB8822147D0 (en) * | 1988-09-21 | 1988-10-26 | Ciba Geigy Ag | Pharmaceutically active combination |
JPH04505554A (ja) * | 1989-02-17 | 1992-10-01 | コドン | 可溶性トロンボモジュリン類似体 |
EP0467987A4 (en) * | 1989-05-01 | 1992-07-08 | The University Of Notre Dame Du Lac | Methods and materials for expression of human plasminogen in a eukaryotic cell system |
US5164304A (en) * | 1989-05-04 | 1992-11-17 | Sri International | Method and vectors for stabilizing hirudin and human laminin b1 expression |
US5087572A (en) * | 1989-12-01 | 1992-02-11 | Genentech, Inc. | Dna encoding human plasminogen modified at the cleavage site |
EP0561034B1 (en) * | 1991-08-26 | 1999-06-09 | IMMUNO Aktiengesellschaft | Direct molecular cloning of a modified chordopox virus genome |
-
1989
- 1989-12-07 GB GB898927722A patent/GB8927722D0/en active Pending
-
1990
- 1990-12-04 NZ NZ236330A patent/NZ236330A/en unknown
- 1990-12-06 PT PT96103A patent/PT96103B/pt not_active IP Right Cessation
- 1990-12-06 PT PT96104A patent/PT96104A/pt unknown
- 1990-12-07 EP EP91900851A patent/EP0502968B1/en not_active Expired - Lifetime
- 1990-12-07 IE IE441790A patent/IE81046B1/en not_active IP Right Cessation
- 1990-12-07 WO PCT/GB1990/001912 patent/WO1991009118A2/en active IP Right Grant
- 1990-12-07 JP JP3501314A patent/JPH05502374A/ja not_active Expired - Lifetime
- 1990-12-07 CA CA002069105A patent/CA2069105A1/en not_active Abandoned
- 1990-12-07 US US07/854,596 patent/US5434073A/en not_active Expired - Fee Related
- 1990-12-07 KR KR1019920701348A patent/KR100188302B1/ko not_active IP Right Cessation
- 1990-12-07 US US07/854,603 patent/US5637492A/en not_active Expired - Lifetime
- 1990-12-07 IL IL9660190A patent/IL96601A/en not_active IP Right Cessation
- 1990-12-07 IL IL96602A patent/IL96602A0/xx unknown
- 1990-12-07 IE IE441690A patent/IE904416A1/en unknown
- 1990-12-07 AT AT91900851T patent/ATE155812T1/de not_active IP Right Cessation
- 1990-12-07 ZA ZA909853A patent/ZA909853B/xx unknown
- 1990-12-07 CA CA002069085A patent/CA2069085C/en not_active Expired - Lifetime
- 1990-12-07 KR KR1019920701305A patent/KR920703818A/ko not_active Application Discontinuation
- 1990-12-07 ZA ZA909854A patent/ZA909854B/xx unknown
- 1990-12-07 DK DK91900851.6T patent/DK0502968T3/da active
- 1990-12-07 JP JP3501315A patent/JP2851423B2/ja not_active Expired - Fee Related
- 1990-12-07 EP EP91900869A patent/EP0504241A1/en not_active Withdrawn
- 1990-12-07 NZ NZ236401A patent/NZ236401A/en unknown
- 1990-12-07 AU AU69540/91A patent/AU644399B2/en not_active Ceased
- 1990-12-07 ES ES91900851T patent/ES2106073T3/es not_active Expired - Lifetime
- 1990-12-07 AU AU69656/91A patent/AU643247B2/en not_active Ceased
- 1990-12-07 WO PCT/GB1990/001911 patent/WO1991009125A1/en not_active Application Discontinuation
- 1990-12-07 DE DE69031127T patent/DE69031127T2/de not_active Expired - Fee Related
-
1992
- 1992-06-05 FI FI922609A patent/FI922609A/fi unknown
- 1992-06-05 NO NO922238A patent/NO305562B1/no not_active IP Right Cessation
- 1992-06-05 NO NO92922237A patent/NO922237L/no unknown
- 1992-06-05 FI FI922610A patent/FI105202B/fi active
-
1993
- 1993-08-30 AU AU44976/93A patent/AU4497693A/en not_active Abandoned
-
1995
- 1995-06-22 HU HU95P/P00384P patent/HU211628A9/hu unknown
-
1997
- 1997-10-09 GR GR970402633T patent/GR3024990T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920703803A (ko) | 활성화 피브린 용해성과 항-혈전성 단백질 | |
JW Fenton et al. | Thrombin structure and function: why thrombin is the primary target for antithrombotics | |
AU724715B2 (en) | A stabilized mixture comprising fibrinogen | |
EP0968008B1 (en) | A stabilized mixture comprising fibrinogen | |
US5374617A (en) | Treatment of bleeding with modified tissue factor in combination with FVIIa | |
DE60133541T2 (de) | Modifizierter faktor viii | |
DE60019122T2 (de) | Veränderter faktor viii | |
Silva et al. | A prothrombin activator from Bothrops erythromelas (jararaca-da-seca) snake venom: characterization and molecular cloning | |
US5084273A (en) | Composition of anticoagulants | |
CA2372929C (en) | Medicament for topical application | |
ES2270460T3 (es) | Un proceso para producir un polipeptido recombinante que involucra la adicion al medio cultivo celular de un inhibidor de proteasas o quimiotripsoinas dependientes de metales. | |
AT405517B (de) | Faktor x-deletionsmutanten und analoge davon | |
WO1998052601A1 (en) | Cleavage of fibrin(ogen) and cross-linked fibrin by fibrinolytic matrix metalloproteinases | |
DE60038312T2 (de) | Faktor x-analog mit einer verbesserten fähigkeit, aktiviert zu werden | |
JP2820699B2 (ja) | 血栓溶解剤 | |
Shih et al. | Plasminogen and plasminogen activator assembly on the human endothelial cell | |
Fenton II | Thrombin functions and antithrombotic intervention | |
US20110053851A1 (en) | Haemostasis-modulating compositions and uses therefor | |
EP0357296A1 (en) | Combination of t-PA and protein C | |
AU611932B2 (en) | Novel complex | |
Schieck et al. | The prothrombin-activating principle from Echis carinatus venom: II. Coagulation studies in vitro and in vivo | |
Agnelli et al. | Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits | |
EP0336508A1 (en) | Recombinant human single-chain urokinase-type plasminogen activator mutant produced by site-specific mutagenesis of lysine 158 to histidine 158 | |
Runge | New horizons in the treatment of coronary artery thrombosis | |
Scheraga et al. | Human Fibrinogen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20090106 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |